Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease

IntroductionTherapeutic options are critically needed for children with refractory very early onset inflammatory bowel disease (VEO-IBD). Our aim was to evaluate clinical response to canakinumab, an anti-IL-1β monoclonal antibody, in patients with VEO-IBD whose phenotype resembles those with monogen...

Full description

Bibliographic Details
Main Authors: Eliana Shaul, Máire A. Conrad, Noor Dawany, Trusha Patel, Megan C. Canavan, Alyssa Baccarella, Sarah Weinbrom, Daniel Aleynick, Kathleen E. Sullivan, Judith R. Kelsen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
canakinumab
very early onset-inflammatory bowel disease
interleukin-1
pediatric
autoinflammatory
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.972114/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.972114/full

Similar Items